TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05996796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colli-Pee Small Volumes
Description: Women will self-collect a first-void urine sample at home upon receipt of the study package using the Colli-Pee Small Volumes (10 mL) device (Novosanis, Belgium). The collector tube is prefilled with a preservative (UCM, Novosanis, Belgium). Women will send the collector vial containing first-void urine along with the informed consent form to the laboratory at University of Antwerp using the prestamped envelope.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colli-Pee Small Volumes
Description: Women will self-collect a first-void urine sample at home upon receipt of the study package using the Colli-Pee Small Volumes (10 mL) device (Novosanis, Belgium). The collector tube is prefilled with a preservative (UCM, Novosanis, Belgium). Women will send the collector vial containing first-void urine along with the informed consent form to the laboratory at University of Antwerp using the prestamped envelope.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evalyn Brush
Description: Women will self-collect a vaginal sample at home upon receipt of the study package using the Evalyn Brush device (Rovers Medical Devices, The Netherlands). Women will send the used brush along with the informed consent form to the laboratory at University of Antwerp using the prestamped envelope.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evalyn Brush
Description: Women will self-collect a vaginal sample at home upon receipt of the study package using the Evalyn Brush device (Rovers Medical Devices, The Netherlands). Women will send the used brush along with the informed consent form to the laboratory at University of Antwerp using the prestamped envelope.
Study: NCT05079490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motor intervention
Description: gross motor skill intervention combined with fitness training
Study: NCT01222650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSO-0400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSO-0400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04361201

Intervention type: PROCEDURE
Intervention: Ligament plastic surgery
Description: Ligament plastic surgery of ankle under arthroscopy for recurrent instable ankle reason and failure of medical treatment.

Intervention type: PROCEDURE
Intervention: Ligament plastic surgery
Description: Ligament plastic surgery of ankle under arthroscopy for recurrent instable ankle reason and failure of medical treatment.

Intervention type: DIAGNOSTIC_TEST
Intervention: RMI and ultrasound
Description: RMI examination at 3 months on operated ankle, and 3 CT scan examinations with elastography module will be performed at planned timeframes.

Intervention type: DIAGNOSTIC_TEST
Intervention: RMI and ultrasound
Description: RMI examination at 3 months on operated ankle, and 3 CT scan examinations with elastography module will be performed at planned timeframes.
Study: NCT05301075

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rhomboid Intercostal and Sub-Serratus block
Description: Rhomboid Intercostal and Sub-Serratus block under ultrasound guidance

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Rhomboid Intercostal and Sub-Serratus block
Description: Rhomboid Intercostal and Sub-Serratus block under ultrasound guidance
Study: NCT05728879

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: APR-TD011 (RLF-TD011)
Description: APR-TD011 (RLF-TD011) wound cleansing spray (drug/device combination product with a 510k clearance that is commercially marketed in the US for use by or on the order of a physician.
Study: NCT03884400

Intervention type: PROCEDURE
Intervention: Specimens obtained from surgical, phlebotomy or other non-invasive procedure
Description: Biospecimen Collection
Study: NCT05611957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3437943
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3437943
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3437943
Description: Administered SC.
Study: NCT04992143

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE first ,and more TACE could be performed when it is necessary.
Study: NCT05636241

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physiotherapy program
Description: The conventional physiotherapy program consists of stretching exercises for lower extremities, strength exercises for core, upper, and lower extremity muscles, sit to stand exercises, and balance exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole body vibration training program
Description: The whole body vibration training program sessions consisted of three 3-min bouts of vibration of 20 Hz and a peak-to-peak amplitude of 2mm with a 3-min rest in between, in addition to conventional physiotherapy exercises for children with cerebral palsy.
Study: NCT04992143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tilelizumab
Description: Tilelizumab 240mg per 3weeks ivgtt within 1 week after the first TACE

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib should be administered 400 mg twice /day orally within 1 week after the first TACE
Study: NCT05637554

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic appendectomy using clipping.
Description: Laparoscopic appendectomy using clipping to secure the base of the appendix.
Study: NCT05037006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane - Neostigmine 30
Description: Neostigmine 30 mcg/kg and atropine 15 mcg/kg when TOFc 3
Study: NCT05637554

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic appendectomy using extracorporeal ligation to secure the base of the appendix.
Description: Laparoscopic appendectomy using extracorporeal ligation to secure the base of the appendix.
Study: NCT04615637

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEG recordings
Description: 1. Classical MEG recordings (patient at rest, normal subjects stimulated with visual, motor, somesthesic and auditory stimuli).~2. MEG recordings with our OPM He4 prototype (patient at rest, normal subjects stimulated with visual, motor, somesthesic and auditory stimuli).
Study: NCT05066672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NV-5138
Description: NV-5138 is a novel, orally bioavailable, selective, direct activator of mTORC1 cellular signaling
Study: NCT05037006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane - Neostigmine 50
Description: Neostigmine 50 mcg/kg and atropine 25 mcg/kg when TOFc 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane - Neostigmine 70
Description: Neostigmine 70 mcg/kg and atropine 35 mcg/kg when TOFc 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIVA - Neostigmine 30
Description: Neostigmine 30 mcg/kg and atropine 15 mcg/kg when TOFc 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIVA - Neostigmine 50
Description: Neostigmine 50 mcg/kg and atropine 25 mcg/kg when TOFc 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIVA - Neostigmine 70
Description: Neostigmine 70 mcg/kg and atropine 35 mcg/kg when TOFc 3
Study: NCT05699005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Packed Red Blood Cells (PRBCs)
Description: Patient will recieve PRBCs transfusion only in case of ScVO2 level\<65% after assessment of patient for optimisation of SaO2 targeting 100%, volume status, ECMO flow (increase to 20% in relevant), pain, anxiety and fever (body temperature \>38°3).~In both groups transfusion may be performed in case massive bleeding according to local protocols, STEMI, Hyperlactatemia \>4 that can be related to oxygen demand and supply DO2/VO2 ratio impairement, in all groups, transfusion should be performed in case of hemolobin level \<7g/dL or worsening of neurological condition (Increase in Neurological SOFA component of 1 and more) related to DO2/VO2 impairement.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Packed Red Blood Cells (PRBCs)
Description: Patient will recieve PRBCs transfusion only in case of ScVO2 level\<65% after assessment of patient for optimisation of SaO2 targeting 100%, volume status, ECMO flow (increase to 20% in relevant), pain, anxiety and fever (body temperature \>38°3).~In both groups transfusion may be performed in case massive bleeding according to local protocols, STEMI, Hyperlactatemia \>4 that can be related to oxygen demand and supply DO2/VO2 ratio impairement, in all groups, transfusion should be performed in case of hemolobin level \<7g/dL or worsening of neurological condition (Increase in Neurological SOFA component of 1 and more) related to DO2/VO2 impairement.
Study: NCT05277337

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: powder BoNT-A (BOTOX/Vistabel)
Description: Botulinum Toxin Type A (BoNT-A) for treatment of glabellar lines; Mode of administration: intramuscular injection
Study: NCT05066672

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matched placebo
Description: matched placebo oral capsules
Study: NCT06158646

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kinematic knee prosthesis
Description: Patients with a kinematically aligned total knee prosthesis and having a post-operative follow-up consultation within at least 1 year after their surgery are consecutively pre-selected according to the eligibility criteria.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: biomechanic knee prosthesis
Description: A group of patients with a mechanically aligned TKA and scheduled for a follow-up consultation 1 year after surgery will be identified to be matched on the aforementioned criteria (sex, age, BMI).
Study: NCT05091320

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical thrombectomy
Description: Mechanical thrombectomy is interventional method and the first line management in large vessel occlusion in acute ischemic stroke

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: medical treatment
Description: medical management of patient according guide lines, either alteplase if presented in it's time window, or anti-platelet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: medical treatment
Description: medical management of patient according guide lines, either alteplase if presented in it's time window, or anti-platelet
Study: NCT05049603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg
Description: One tablet/day, given approximately at 10 pm, after dinner and before going to bed, for 24 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet/day, given approximately at 10 pm, after dinner and before going to bed, for 24 weeks
Study: NCT06095388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JR-441
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JR-441
Description: IV infusion
Study: NCT05429567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: All patients underwent combined spinal and epidural anesthesia (CSEA) with 2 ml of 0.5 % hyperbaric bupivacaine and 25 ug fentanyl administered using a 27-gauge Whitacre spinal needle and an 18-gauge Tuohy needle in the epidural space. The epidural space was identified utilizing the loss of resistance approach

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: All patients underwent combined spinal and epidural anesthesia (CSEA) with 2 ml of 0.5 % hyperbaric bupivacaine and 25 ug fentanyl administered using a 27-gauge Whitacre spinal needle and an 18-gauge Tuohy needle in the epidural space. The epidural space was identified utilizing the loss of resistance approach
Study: NCT05347641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab
Description: Penpulimab + RMA regimen:~Rituximab 375 mg/m2 d0 iv Methotrexate (MTX) 3.5g/m2 drip D1 Cytarabine \* (ARA-C) 1-2g/m2 q12H D2-3 iv Penpulimab 200 mg iv D5
Study: NCT04336930

Intervention type: DIAGNOSTIC_TEST
Intervention: Pupillary pain index (PPI)
Description: Measurement of PPI with a pupillometer
Study: NCT05606133

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: NavDx(R)
Description: NavDx® is a blood test that utilizes digital droplet PCR in order to quantify fragments of tumor-specific DNA shed by HPV-associated cancer cells in the blood. The technology has the ability to distinguish tumor-tissue modified virus particles present in the plasma cell-free DNA from non-cancer associated sources of HPV DNA.
Study: NCT04957186

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Collection of postoperative information
Description: The EORTC BR45 questionnaire will be used to gather information from patients regarding possible post-operative complications recorded via electronic patient-reported outcomes (pain, swelling, hypersensitivity etc.) as well as via the interviews with the state-registered coordinating nurse.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Analysis of postoperative information collected from patients
Description: All post-operative complications recorded via electronic patient-reported outcomes (pain, swelling, hypersensitivity etc.) as well as via the interviews with the state-registered coordinating nurse will be analyzed with the aim of proposing an appropriate care pathway.
Study: NCT06645041

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D (Cholecalciferol )
Description: The hypertensive patients with vitamin D deficiency will receive a Vitamin D capsule with a dose of 25,000 IU. They will be asked to receive a capsule per week for 8 subsequent weeks and re-visit the hospital two weeks from the final dose.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule(s)
Description: The hypertensive patients with vitamin D deficiency will receive a Placebo capsule. They will be asked to receive a capsule per week for 8 subsequent weeks and re-visit the hospital two weeks from the final dose.
Study: NCT06420310

Intervention type: OTHER
Intervention: exposure to pesticides
Description: based on work exposures to pesticides

Intervention type: OTHER
Intervention: exposure to pesticides
Description: based on work exposures to pesticides
Study: NCT04989608

Intervention type: OTHER
Group type: OTHER
Intervention: Neuroimaging
Description: realization of a neuroimaging 1 and 3 years after the transient ischemic accident

Intervention type: OTHER
Group type: OTHER
Intervention: Neuroimaging
Description: realization of a neuroimaging 1 and 3 years after the transient ischemic accident
Study: NCT06028633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: pembrolizumab 200mg IV on day 1 for every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: lenvatinib 8mg taken orally every day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin-bound paclitaxel
Description: albumin-bound paclitaxel IV 100mg/m2 D1, 8 every 3 weeks
Study: NCT05313542

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Physical Activity in the format of Self-defence Training

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical Activity
Description: Physical Activity in the format of Self-defence Training
Study: NCT05624333

Intervention type: OTHER
Group type: OTHER
Intervention: Vegan diet (intervention)
Description: The intervention diet will be a fully controlled vegan diet that will be consumed for a duration of 10 days. No animal-based food products will be included in the diet.
Study: NCT05429879

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preferred Music Arm
Description: Patients will choose their preferred music to be played during the cystoscopy procedure. No music will be played prior to or immediately after the flexible cystoscopy procedure. Music will be delivered via a speaker allowing for communication between the urologist and the patient during the procedure. Aside from addition of music, standard of care will not be impacted.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical Music Arm
Description: A standardized playlist of copyright free classical music will be played during the cystoscopy procedure. No music will be played prior to or immediately after the flexible cystoscopy procedure. Music will be delivered via a speaker allowing for communication between the urologist and the patient during the procedure. Aside from addition of music, standard of care will not be impacted.
Study: NCT05606926

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy program
Description: Flexibility exercises to restore joint mobility of soft tissues, Static and dynamic balance exercises, Functional gait training , Functional strengthening exercises will be conducted three times a week, for three consecutive months.

Intervention type: OTHER
Group type: OTHER
Intervention: physical therapy program
Description: Flexibility exercises to restore joint mobility of soft tissues, Static and dynamic balance exercises, Functional gait training , Functional strengthening exercises will be conducted three times a week, for three consecutive months.

Intervention type: OTHER
Group type: OTHER
Intervention: whole body vibration (without extra weight vest)
Description: 9 minutes of three sets of 3-min semi-squats on the vibration platform. three times a week, for three consecutive months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole body vibration (with weight vest)
Description: The extra-weight applied in the vest will be calculated as 10% of the child body weight. The vest is designed to allow small bags of sand with different weights that are distributed equally on anterior-posterior and mediolateral plans.
Study: NCT05624333

Intervention type: OTHER
Group type: OTHER
Intervention: Omnivorous diet (control)
Description: The control diet will be an a priori composed controlled omnivorous diet with a duration of 10 days. The omnivorous diet and the vegan diet will be isocaloric and isonitrogenous.
Study: NCT05423405

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: selected acupoint pressure
Study: NCT05423405

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Acupressure
Description: selected acupoint pressure
Study: NCT05990855

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: eCBTi-obj
Description: eCBTi based on objective sleep measures recorded by the Muse S headband.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eCBTi-subj
Description: eCBTi based on standard subjective sleep measures recorded on the sleep diary.
Study: NCT05489445

Intervention type: DEVICE
Intervention: KODEX - EPD
Description: A patient that is already clinically indicated to undergo cryoballoon ablation for atrial fibillation will use the The KODEX - EPD™ Cardiac Imaging and Navigation electrophysiological (EP) System. This is an imaging system which allows the physician real-time visualization of the catheters in a patients heart during the procedure, as well as display of cardiac images of the patients heart in a number of different formats. The KODEX - EPD system used in this study is cleared for commercial use by the FDA and therefore, it's use in this study constitutes as standard clinical use.
Study: NCT04792710

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metronidazole
Description: Metronidazole 500 mg intravenous stat dose prior to skin incision

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole 500 mg intravenous stat dose prior to skin incision
Study: NCT06436456

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online psychological intervention
Description: The online intervention constitutes a psychological intervention rooted in therapeutic principals of Acceptance and Commitment Therapy (ACT) and Cognitive Behavioral Therapy (CBT). Comprising 7 obligatory modules and 4 optional modules, the intervention is facilitated through an online platform, offering a text-based self-help program. Patients receive written guidance from a psychologist at Steno Diabetes Center Odense (SDCO). While undergoing intervention, patients have the option to seek clarification or assistance from the psychologist if encountered with queries or difficulties. It is anticipated that patients will progress through approximately one module per week. Following completion of the intervention, patients retain access to the online intervention for a duration of 3 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual psychological intervention
Description: In the individual intervention, patients undergo personalized therapy administered by the assigned psychologist from SDCO. This treatment approach is grounded in the principles of Acceptance and Commitment Therapy (ACT) and Cognitive Behavioral Therapy (CBT). Delivery of treatment can occur through various modalities, including telephone, video conferencing, or in-person sessions, tailored to accommodate the preferences and requirements of the patient. A maximum of 10 treatment sessions are available for each patient.
Study: NCT05914701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir for secondary prophylaxis
Description: For enrolled patients, Letermovir would be administered at a dose of 480 mg per day (or 240 mg per day in patients taking cyclosporine). The regimen duration of dosing was approximately 120 days or 16 weeks. Or physicians could adjust regimen duration according to the CMV infection risk factors.
Study: NCT05758090

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NIPE monitor
Description: Procedure/Surgery: NIPE protocol. Give intraoperative fentanyl according to NIPE value. NIPE score 50-70 indicates optimal narcotic effect. NIPE score \> 70 indicated overdosage of narcotic and narcotic should be withheld. NIPE score \< 50 indicates inadequate narcotic and narcotic should be given.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Procedure/Surgery: Standard protocol. Give intraoperative fentanyl according to vital signs.